Vanguard Group Inc Avrobio, Inc. Transaction History

Vanguard Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.15 - $1.48 $321,310 - $413,512	279,400 Added 17.44%	1,881,234 $2.41 Million
Q4 2023 Feb 14, 2024	BUY	$1.22 - $1.62 $32,940 - $43,740	27,000 Added 1.71%	1,601,834 $2.18 Million
Q3 2023 Nov 14, 2023	BUY	$0.98 - $1.62 $385,826 - $637,794	393,700 Added 33.33%	1,574,834 $2.43 Million
Q1 2023 May 15, 2023	BUY	$0.76 - $1.82 $17,386 - $41,636	22,877 Added 1.98%	1,181,134 $1.18 Million
Q4 2022 Feb 10, 2023	BUY	$0.64 - $0.91 $603 - $858	943 Added 0.08%	1,158,257 $822,000
Q3 2022 Nov 14, 2022	BUY	$0.68 - $1.11 $93,042 - $151,877	136,827 Added 13.41%	1,157,314 $743,000
Q2 2022 Aug 12, 2022	SELL	$0.75 - $1.33 $39,510 - $70,065	-52,681 Reduced 4.91%	1,020,487 $939,000
Q1 2022 May 13, 2022	SELL	$1.29 - $4.04 $781,661 - $2.45 Million	-605,939 Reduced 36.09%	1,073,168 $1.42 Million
Q4 2021 Feb 14, 2022	SELL	$3.45 - $6.05 $142,764 - $250,355	-41,381 Reduced 2.41%	1,679,107 $6.46 Million
Q3 2021 Nov 12, 2021	BUY	$5.53 - $9.28 $83,314 - $139,812	15,066 Added 0.88%	1,720,488 $9.6 Million
Q2 2021 Aug 13, 2021	BUY	$7.84 - $12.6 $13.4 Million - $21.5 Million	1,705,422 New	1,705,422 $15.2 Million

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.